Literature DB >> 1709604

Insulin and glucagon levels in fulminant hepatic failure in man.

F Fiaccadori1, G Pedretti, C Ferrari, P Pizzaferri, O Riggio, N Orlandi, A Pezzarossa.   

Abstract

The behavior of insulin and glucagon and related metabolic substrates was assayed in plasma of patients with fulminant hepatic failure. All 12 subjects were provided the same nutritional support. High levels of insulin and glucagon were present at all times and no difference was observed between surviving patients (four) and those who died (8). Elevated values for branched-chain and aromatic amino acids as well as alanine were present. Statistically significant lower levels of aromatic amino acids and consequently a greater branched chain-aromatic amino acid ratio was found in surviving vs nonsurviving patients. A significantly greater level of alpha-fetoprotein was found in patients who survived as compared to those who died.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709604     DOI: 10.1007/bf01311240

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Effect of insulin and glucagon on fulminant murine hepatitis.

Authors:  M Farivar; J R Wands; K J Isselbacher; N L Bucher
Journal:  N Engl J Med       Date:  1976-12-30       Impact factor: 91.245

2.  Hormonal factors and liver growth.

Authors:  N L Bucher; U Patel; S Cohen
Journal:  Adv Enzyme Regul       Date:  1977 Oct 3-4

3.  Glucoregulation in acute liver failure.

Authors:  H Vilstrup; J Iversen; N Tygstrup
Journal:  Eur J Clin Invest       Date:  1986-06       Impact factor: 4.686

4.  Glucose tolerance and metabolic changes in human viral hepatitis.

Authors:  C O Record; K G Alberti; D H Williamson; R Wright
Journal:  Clin Sci Mol Med       Date:  1973-11

5.  Glucose homeostasis in viral hepatitis.

Authors:  P Felig; W V Brown; R A Levine; G Klatskin
Journal:  N Engl J Med       Date:  1970-12-24       Impact factor: 91.245

6.  Plasma and cerebrospinal fluid amino acid patterns in hepatic encephalopathy.

Authors:  A Cascino; C Cangiano; F Fiaccadori; F Ghinelli; M Merli; G Pelosi; O Riggio; F Rossi Fanelli; D Sacchini; M Stortoni; L Capocaccia
Journal:  Dig Dis Sci       Date:  1982-09       Impact factor: 3.199

7.  Insulin and glucagon infusion in the treatment of liver failure.

Authors:  J B Jaspan; R L Landau; J Schneider
Journal:  Arch Intern Med       Date:  1984-10

8.  Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs.

Authors:  T E Starzl; K Watanabe; K A Porter; C W Putnam
Journal:  Lancet       Date:  1976-04-17       Impact factor: 79.321

9.  Human hepatocyte growth factor in plasma from patients with fulminant hepatic failure.

Authors:  E Gohda; H Tsubouchi; H Nakayama; S Hirono; K Takahashi; M Koura; S Hashimoto; Y Daikuhara
Journal:  Exp Cell Res       Date:  1986-09       Impact factor: 3.905

10.  Regulation of hepatic regeneration in rats by synergistic action of insulin and glucagon.

Authors:  M L Bucher; M N Swaffield
Journal:  Proc Natl Acad Sci U S A       Date:  1975-03       Impact factor: 11.205

View more
  3 in total

Review 1.  Treatment of acute liver failure.

Authors:  K H Boeker
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

2.  Pro-inflammatory cytokine release and mediation of the acute phase protein response in fulminant hepatic failure.

Authors:  S J Wigmore; T S Walsh; A Lee; J A Ross
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

3.  Serum hepatocyte growth factor as an index of extensive catabolism of patients awaiting liver transplantation.

Authors:  C Miki; A D Mayer; J A Buckels; K Iriyama; H Suzuki; P McMaster
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.